MX2022001796A - Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. - Google Patents

Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.

Info

Publication number
MX2022001796A
MX2022001796A MX2022001796A MX2022001796A MX2022001796A MX 2022001796 A MX2022001796 A MX 2022001796A MX 2022001796 A MX2022001796 A MX 2022001796A MX 2022001796 A MX2022001796 A MX 2022001796A MX 2022001796 A MX2022001796 A MX 2022001796A
Authority
MX
Mexico
Prior art keywords
symptoms associated
veisalgia
compositions
methods
inhibit symptoms
Prior art date
Application number
MX2022001796A
Other languages
English (en)
Inventor
James M Iversen
Jacqueline M Iversen
Original Assignee
Jacqueline M Iversen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacqueline M Iversen filed Critical Jacqueline M Iversen
Publication of MX2022001796A publication Critical patent/MX2022001796A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a un método para reducir o evitar los síntomas asociados con la ingesta de alcohol. El método comprende administrarle a un sujeto una cantidad efectiva de una composición farmacéutica antes de la ingesta de alcohol. La composición farmacéutica comprende un fármaco antiinflamatorio no esteroideo y un antihistamínico H1.
MX2022001796A 2015-03-26 2017-09-25 Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. MX2022001796A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562138665P 2015-03-26 2015-03-26

Publications (1)

Publication Number Publication Date
MX2022001796A true MX2022001796A (es) 2022-03-17

Family

ID=56976188

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012132A MX2017012132A (es) 2015-03-26 2016-03-18 Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
MX2022001796A MX2022001796A (es) 2015-03-26 2017-09-25 Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017012132A MX2017012132A (es) 2015-03-26 2016-03-18 Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.

Country Status (15)

Country Link
US (3) US10420756B2 (es)
EP (2) EP3273952B1 (es)
JP (1) JP6851365B2 (es)
KR (1) KR102597910B1 (es)
CN (2) CN115887456A (es)
AU (1) AU2016235484B2 (es)
BR (1) BR112017020307B1 (es)
CA (1) CA2980162A1 (es)
ES (1) ES2926494T3 (es)
IL (1) IL254641B2 (es)
MX (2) MX2017012132A (es)
NZ (1) NZ735777A (es)
PL (1) PL3273952T3 (es)
WO (1) WO2016154028A1 (es)
ZA (1) ZA201706794B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887456A (zh) * 2015-03-26 2023-04-04 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
US10874653B2 (en) 2017-08-30 2020-12-29 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit adverse effects associated with vaccinations
US11129803B2 (en) 2017-09-18 2021-09-28 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit tolerance to opioids
US10675261B2 (en) * 2017-09-18 2020-06-09 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit dependence on opioids
CA3076193A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit symptoms associated with opioid withdrawal
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075426A (en) 1976-03-12 1978-02-21 Harvey Mitchell Gould Parallel silent communicator
US4496548A (en) * 1983-02-04 1985-01-29 Moldowan Mervin J Composition and method for reducing hangover
US5053396A (en) 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US4975426A (en) 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
WO1992005783A1 (en) * 1990-09-28 1992-04-16 Merck & Co., Inc. Ibuprofen-antihistamine combinations
DE9320925U1 (de) 1992-08-03 1995-08-31 Sepracor Inc Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
EP0766960B1 (en) 1995-04-21 2003-09-17 Sekisui Kagaku Kogyo Kabushiki Kaisha External preparations for treating dermatoses
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
DE19708209C2 (de) 1997-02-28 2000-03-02 Hans Juergen Pauling Wiederaufladbare Batterieanordnung und deren Verwendung
US20050281751A1 (en) 1997-07-21 2005-12-22 Bruce Levin Directed intranasal administration of pharmaceutical agents
CA2304005A1 (en) * 1997-09-19 1999-04-01 The Procter & Gamble Company Compositions and methods for treating respiratory disorders
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20030181495A1 (en) 1998-06-23 2003-09-25 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6697361B2 (en) 1998-09-15 2004-02-24 Nortel Networks Limited Method and apparatus for stream aggregation in a multiprotocol label switching network environment
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
WO2003009834A1 (en) 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
JP2005529840A (ja) 2001-10-16 2005-10-06 ヒプニオン， インコーポレイテッド Ｃｎｓ標的モジュレータを使用するｃｎｓ障害の治療
US7189757B2 (en) 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
GB0128674D0 (en) 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
EP1471913A2 (en) 2002-01-18 2004-11-03 Hypnion Inc. Treatment of sleep disorders using sleep target modulators
DE10223147A1 (de) 2002-05-16 2003-11-27 Newfrey Llc Fügesystemkopf, Fügesystem und Verfahren zum Zuführen und Fügen von Elementen
WO2004016268A1 (en) 2002-08-15 2004-02-26 Tan Oon T Composition and method for controlling alcohol-induced facial flushing in susceptible humans
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
TWI313598B (en) * 2002-12-18 2009-08-21 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
GB0312419D0 (en) 2003-05-30 2003-07-02 Boots Healthcare Int Ltd Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess
GB0312425D0 (en) 2003-05-30 2003-07-09 Boots Co Plc Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith
US20070292498A1 (en) 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US20080021083A1 (en) 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
GB2435410B (en) * 2004-04-21 2007-12-05 Silent Gliss Internat Ltd Improvements in or relating to curtain heading systems
WO2006018997A1 (ja) 2004-08-18 2006-02-23 Medrx Co., Ltd. 外用剤
WO2006034414A2 (en) 2004-09-21 2006-03-30 Hypnion, Inc. Loxapine analogs and methods of use thereof
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
WO2006049734A2 (en) 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
US7976865B2 (en) 2004-12-15 2011-07-12 Nipro Patch Co., Ltd. Medical tape preparation
EP1824470B1 (en) 2004-12-17 2014-08-06 Alan B. Cash Method for extending lifespan and delaying the onset of age-related disease
JPWO2006087968A1 (ja) 2005-02-17 2008-07-03 角治 東條 眼科用固形外用薬剤
US20070093520A1 (en) 2005-04-15 2007-04-26 Caras Steven D Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
US20070196518A1 (en) 2005-12-15 2007-08-23 Karol Wojewnik Composition and Method for Mitigating a Negative Effect of Alcohol Consumption
WO2007092334A1 (en) 2006-02-02 2007-08-16 Hypnion, Inc. Method of treating sleep disorders
WO2007092333A1 (en) 2006-02-03 2007-08-16 Hypnion, Inc. Use of olopatadine for treating sleep disorders
GB2435418A (en) 2006-02-28 2007-08-29 Amalan Selvarajah Composition for preventing and alleviating alcohol hangover
WO2007103474A2 (en) 2006-03-07 2007-09-13 University Of Florida Research Foundation, Inc. Drug adherence monitoring system
US20080131532A1 (en) 2006-10-17 2008-06-05 Lorn Leitman Fast asleep
CA2667207A1 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
MX2009006672A (es) 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
CA2677205A1 (en) 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
US20110065628A1 (en) 2007-08-27 2011-03-17 University Of Virginia Patent Foundation Medication Combinations for the Treatment of Alcoholism and Drug Addiction
US20090156982A1 (en) 2007-09-06 2009-06-18 Arezou Petrie Transdermal treatment device and method
MX2010004265A (es) 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
AU2009204360B2 (en) 2008-01-04 2014-12-18 Src, Inc. The use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound and single dose compositions thereof
MY160074A (en) * 2008-01-24 2017-02-15 Raptor Therapeutics Inc Protopanaxadiol-type ginsenoside compositions and uses thereof
US20090258869A1 (en) 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
EA019200B1 (ru) 2008-02-28 2014-01-30 Юниверсити Оф Вирджиния Пэтент Фаундейшн Способ прогнозирования предрасположенности к развитию аддиктивного заболевания или расстройства (варианты)
AU2009251743A1 (en) * 2008-05-30 2009-12-03 Fairfield Clinical Trials, Llc Method and composition for skin inflammation and discoloration
CA2765866C (en) 2008-06-20 2016-06-21 Alphapharm Pty Ltd Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid
EP2995303A1 (en) 2009-07-10 2016-03-16 President and Fellows of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
US20130029970A1 (en) 2009-07-10 2013-01-31 Ironwood Pharmaceuticals, Inc CB Receptor Agonists
WO2011071996A1 (en) 2009-12-08 2011-06-16 Ironwood Pharmaceuticals, Inc. Faah inhibitors
WO2011075688A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
WO2012048294A2 (en) 2010-10-07 2012-04-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012088431A1 (en) 2010-12-23 2012-06-28 Ironwood Pharmaceuticals, Inc. Faah inhibitors
EP2680828A4 (en) 2011-02-28 2014-07-30 Technologies Khlôros Inc MASTICABLE VEHICLE FOR ORAL ABSORPTION
CN103702685B (zh) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
US9161957B2 (en) 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
JP6276944B2 (ja) * 2013-08-29 2018-02-07 興和株式会社 フェキソフェナジンとｎｓａｉｄ含有医薬組成物
WO2015073573A1 (en) * 2013-11-14 2015-05-21 Jacobs Michael M Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
CN115887456A (zh) 2015-03-26 2023-04-04 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis

Also Published As

Publication number Publication date
CA2980162A1 (en) 2016-09-29
CN107635549A (zh) 2018-01-26
BR112017020307A2 (pt) 2018-06-05
US11464766B2 (en) 2022-10-11
JP2018509470A (ja) 2018-04-05
AU2016235484B2 (en) 2021-02-18
EP3273952A4 (en) 2018-11-21
JP6851365B2 (ja) 2021-03-31
IL254641A0 (en) 2017-11-30
EP3273952A1 (en) 2018-01-31
US20230064685A1 (en) 2023-03-02
EP3273952B1 (en) 2022-06-15
ES2926494T3 (es) 2022-10-26
MX2017012132A (es) 2018-07-06
US20160279112A1 (en) 2016-09-29
KR20170131647A (ko) 2017-11-29
WO2016154028A1 (en) 2016-09-29
CN115887456A (zh) 2023-04-04
IL254641B2 (en) 2024-01-01
NZ735777A (en) 2023-03-31
ZA201706794B (en) 2019-02-27
IL254641B1 (en) 2023-09-01
PL3273952T3 (pl) 2022-11-14
EP3973957A1 (en) 2022-03-30
AU2016235484A1 (en) 2017-10-12
US10420756B2 (en) 2019-09-24
US20200009119A1 (en) 2020-01-09
KR102597910B1 (ko) 2023-11-02
BR112017020307B1 (pt) 2023-11-07

Similar Documents

Publication Publication Date Title
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2018001268A (es) Combinacion de antagonista de pd-1 con un inhibidor de egfr.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
WO2014153009A3 (en) Thiosaccharide mucolytic agents
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
PH12015501783B1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
IN2013MU02370A (es)
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
TW201611830A (en) Pharmaceutical formulation for reducing bladder spasms and method of use thereof
UY35748A (es) Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple
PH12020500472A1 (en) Autotaxin inhibitor compounds
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
MX2013008995A (es) Composicion farmaceutica para el tratamiento del dolor.